.04% Atropine Better than .01% or Ortho-K in Managing Myopia

 A Chinese clinical trial compared low-dose (0.01%) and mid-dose (0.04%) atropine eye drops with orthokeratology (ortho-K) to manage myopia in children. Over two years, 0.04% atropine was the most effective at slowing eye growth (axial elongation), which drives myopia progression. It outperformed both 0.01% atropine and ortho-K. However, 0.04% caused more light sensitivity (photophobia), though this declined over time.


Critics of the study pointed out that subgroup sizes were small and behavior during the COVID-19 lockdowns (like time spent indoors) wasn’t accounted for, which could have skewed results. They also questioned conclusions about age-specific effectiveness due to limited data. Still, the overall finding stands: 0.01% atropine is not enough for effective myopia control, and higher doses like 0.04% may offer better results.

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH